RXRX Recursion Pharmaceuticals
AI drug discovery with NVIDIA-backed compute
Fundamentals from public market data, refreshed daily (2026-10-24 02:59 UTC). Figures in reporting currency.
RXRX · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-08-05EarningsMiss / cut
Reported EPS -0.25 vs -0.23 expected (-6.8% surprise).
-
7
2026-05-06EarningsBeat / raise
Reported EPS -0.22 vs -0.26 expected (+14.4% surprise).
-
6
2026-02-25EarningsBeat / raise
Reported EPS -0.21 vs -0.32 expected (+33.3% surprise).
-
5
2025-11-05EarningsBeat / raise
Reported EPS -0.36 vs -0.38 expected (+5.7% surprise).
-
4
2025-08-05EarningsMiss / cut
Reported EPS -0.41 vs -0.35 expected (-16.0% surprise).
-
3
2025-05-05EarningsBeat / raise
Reported EPS -0.5 vs -0.52 expected (+3.1% surprise).
-
2
2025-02-28EarningsMiss / cut
Reported EPS -0.53 vs -0.42 expected (-27.2% surprise).
-
1
2024-11-06EarningsMiss / cut
Reported EPS -0.34 vs -0.33 expected (-2.1% surprise).
Latest headlines
Auto-updated daily- Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing2026-10-20
- Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?2026-10-19
- Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone2026-10-19
- Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions2026-10-19
- Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone2026-10-18
- Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar2026-10-15
- RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today?2026-10-15
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.23 | -0.25 | −6.8% |
| 2026-05-06 | -0.26 | -0.22 | +14.4% |
| 2026-02-25 | -0.32 | -0.21 | +33.3% |
| 2025-11-05 | -0.38 | -0.36 | +5.7% |
| 2025-08-05 | -0.35 | -0.41 | −16.0% |
| 2025-05-05 | -0.52 | -0.5 | +3.1% |
| 2025-02-28 | -0.42 | -0.53 | −27.2% |
| 2024-11-06 | -0.33 | -0.34 | −2.1% |
| 2024-08-08 | -0.38 | -0.4 | −4.2% |
| 2024-05-09 | -0.43 | -0.39 | +8.6% |
| 2024-02-27 | -0.45 | -0.42 | +6.4% |
| 2023-11-09 | -0.39 | -0.43 | −11.6% |
| 2023-08-08 | -0.37 | -0.38 | −1.3% |
| 2023-05-08 | -0.35 | -0.34 | +3.0% |
| 2023-02-27 | -0.24 | -0.3 | −26.8% |
| 2022-11-08 | -0.38 | -0.35 | +7.6% |
| 2022-08-09 | -0.37 | -0.38 | −1.8% |
| 2022-05-10 | 0.51 | -0.33 | −164.7% |
| 2022-03-23 | -0.31 | -0.38 | −23.6% |
| 2021-11-10 | -0.28 | -0.28 | +0.1% |
| 2021-08-13 | -0.24 | -0.31 | −28.6% |
| 2021-05-12 | -0.23 | -0.23 | +1.0% |
About Recursion Pharmaceuticals
Website ↗Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes R…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| SDGR Schrödinger | Physics-plus-AI molecular design software | $24.60 | +3.36% | −14.7% | +37.6% | |
| ABSI Absci | Generative-AI antibody design | $9.55 | +4.03% | −1.9% | +173.6% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.15 | +2.81% | −4.3% | +255.3% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $66.46 | −1.71% | −21.8% | +12.6% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.